Abstract
THIS REPORT:
- Provides an in-depth analysis of the global market for generic
pharmaceuticals, with discussion of the trends most affecting the industry
including an increased demand for generics
- Contains global market forecasts for sales in the generic pharmaceuticals
market through 2014
- Reviews the major categories of prescription drugs that are traditional
targets for generic copies
- Includes profiles of leading suppliers of generics together with a
description of their products and market share
- Describes the regulatory environment for production and marketing of
generics in the three main regulatory regions of the US, EU and Japan.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology, and industry
analyses to help readers quantify and qualify the market for prescription
generic drugs. Important trends are identified and sales forecasts by product
categories and major country markets are provided through 2014; these are
based on industry sources and considered assessment of the regulatory
environment, healthcare policies, demographics, and other factors that
directly affect the generic drug market. The wider economic environment is
also taken into account.
The report examines strategies employed by companies specializing in generics
to meet the challenges of this highly competitive market, while also
summarizing strategies employed by "originator" companies to forestall generic
competition.
REASONS FOR DOING THE STUDY
- This is a time of growth and change for the generic pharmaceutical sector.
Major aspects which combine to create an opportunity for an up-to date market
analysis include the following:
- The demand for generics is increasing steadily because of pressure to
control healthcare costs. At the same time fierce price competition in this
area has put some companies in difficulties because of slashed profit margins.
The main result has been a wave of M&A activity, and the rise of
"supergenerics" offering added value as well as low prices. Not all
traditional companies are placed to exploit this trend.
- A major growth driver for the generics sector is the fact that several
blockbuster pharmaceutical brands are coming off-patent and are therefore open
to generic competition. But the "originator" companies are deploying
formidable strategies to protect their franchise, including marketing their
own branded generics.
- With first-generation biopharmaceutical products reaching the end of their
patent lives, a whole new market field - biogenerics, or biosimilars - is
opening up, for those generics companies capable of (or prepared to buy-in)
the technological expertise required.
- The international landscape is changing for generics as for all
pharmaceuticals. China, India, Eastern European countries and Brazil are among
rising centers of generic activity.
SCOPE OF REPORT
This report discusses the implications of all the above-mentioned trends, in
the context of the current size and growth of the generics market, both in
global terms and analyzed by the most important national markets. The nature
and structure of the generics industry is discussed, with profiles of the
leading 10 to 20 generics companies, and an update on M&A activity. Five-year
sales forecasts are provided for the national markets and the major
therapeutic categories of products involved.
Market figures are based on revenues at the manufacturer level and are
projected at 2009-dollar value without attempting to predict the effect of
inflation/deflation.
Therapeutic categories quantified and forecast include antibacterials,
antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs
(e.g., hypolipidaemics and antihypertensives) and drugs for respiratory
conditions including asthma and COPD.
METHODOLOGY
Primary research includes interviews with leading individuals in generics
companies, industry associations and regulatory bodies. Primary sources of
published data include company annual reports, SEC filings, and government and
industry publications. Secondary sources consist of literature searches,
industry journals and other commercial publications. Data for market estimates
and forecasts are pooled from a range of sources, critically assessed by BCC.
INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of
individuals involved in the generics marketplace, including company senior
management executives seeking to base their strategic decisions on the best
available information on market forces and trends. However it is also aimed at
managers and executives in marketing, research, planning and sales departments
who need readable, comprehensive and up-to-date background on the marketplace
in which they are operating.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives,
government agencies and regulatory bodies, and surveys of physicians and
pharmacists. Company annual reports and SEC filings, journal articles, and
data from healthcare institutions were also mined, as well as publications of
relevant trade associations such as the Generic Pharmaceutical Association
(GPhA) and the European Generic Medicines Association (EGA).
| 
View Cart
